Characterization of Localized Osteosarcoma of the Extremity in Children, Adolescents, and Young Adults From a Single Institution in South Texas
| Autor: | Josefine Heim-Hall, Ronald P. Williams, John E Cornell, Jaclyn Y. Hung, Norma S. Ketchum, Alisha Z. Jiwani, Aaron J. Sugalski, Anne-Marie R Langevin |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
Male
Pediatrics preadolescent Hispanic Kaplan-Meier Estimate 0302 clinical medicine Epidemiology Mexican Americans Young adult Child Bone growth 0303 health sciences Standard treatment Incidence (epidemiology) Hematology Texas 3. Good health Oncology 030220 oncology & carcinogenesis Child Preschool Cohort outcome Osteosarcoma Female Adult medicine.medical_specialty pediatrics Adolescent Bone Neoplasms Disease-Free Survival 03 medical and health sciences Necrosis Young Adult Age Distribution Predictive Value of Tests osteosarcoma medicine Humans 030304 developmental biology Proportional Hazards Models Retrospective Studies business.industry Retrospective cohort study medicine.disease Surgery Pediatrics Perinatology and Child Health Multivariate Analysis Neoplasm Recurrence Local business Online Articles: Original Articles |
| Zdroj: | Journal of Pediatric Hematology/Oncology |
| ISSN: | 1536-3678 1077-4114 |
| Popis: | Osteosarcoma is the most common malignant bone tumor in children, adolescents, and young adults, with about 400 new cases diagnosed each year in the United States. It accounts for approximately 60% of all malignant bone tumors diagnosed in patients before the age of 20 with the peak incidence associated with puberty.1 Although osteosarcoma can occur in the axial skeleton, it typically presents in the metaphysis of long bones, a site of rapid bone growth during adolescence. The standard treatment for high-grade osteosarcoma requires both surgery and chemotherapy given preoperatively (neoadjuvant) and/or postoperatively. Despite improved surgical outcomes and efforts to intensify therapy, the 5-year event-free survival (EFS) remains 65% with no significant improvement in the past 20 years.2 In studies conducted pertaining to osteosarcoma outcome in pediatrics, only 10% to 15% of the cohorts are Hispanics. A study by Mirabello et al3 based on data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results Program, indicates a higher incidence and slightly poorer outcome of osteosarcoma in Hispanics when compared with non-Hispanics. Hispanic patients that are reported in this studies come from a variety of locations including Mexico, South America, Cuba, and Latin America. In this study we performed a retrospective analysis of the characteristics and outcomes in patients with localized high-grade osteosarcoma of the extremity diagnosed under the age of 30 treated at a single institution, University of Texas Health Science Center at San Antonio (UTHSCSA), over an 11-year period. The patients in this study were 70% Hispanic, homogenously of Mexican American ancestry, therefore giving us a unique cohort to study. To the best of our knowledge, this is the largest series composed of such patients. Interestingly, we found a decreased survival of preadolescent patients compared with the patients who were between 12 and 30 years old at diagnosis. Furthermore, our data suggests that tumor necrosis after neoadjuvant chemotherapy might not be directly predictive of outcome. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|